timothy sykes logo
IBRX Stock Rattled As FDA Warning Triggers Class Actions Thumbnail
G Google News

IBRX Stock Rattled As FDA Warning Triggers Class Actions

JACK KELLOGG•UPDATED APR. 24, 2026, 5:05 PM ET
Reviewed by Tim Sykesand Fact-checked by Ellis Hobbs

ImmunityBio Inc. stocks have been trading down by -8.42 percent after trial setback headlines fueled renewed investor concern.

Candlestick Chart

Live Update At 17:05:26 EDT: On Friday, April 24, 2026 ImmunityBio Inc. stock [NASDAQ: IBRX] is trending down by -8.42%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Traders scanning ImmunityBio (IBRX) right now see a classic high‑risk biotech story wrapped in fresh headline pressure. On the tape, IBRX has been grinding in the high‑$7s to low‑$8s, with recent daily closes mostly between $7.14 and $8.20. The latest session saw IBRX open at $8.16 and fade to $7.44, a clear intraday reversal that matches the negative news cycle.

Intraday, the 5‑minute chart shows IBRX trading in a tight band between roughly $7.40 and $7.70 into the close, with volume‑driven action earlier around $8.00–$8.20. That pattern says momentum is cooling and day traders are scalping small moves instead of chasing a trend.

Fundamentals underline the risk. ImmunityBio booked about $113.3M in revenue over the trailing period, but margins are deeply negative and the company is still burning cash, with recent quarterly free cash flow around -$71.7M. Return on assets sits near -80% to -88%, and book value per share is negative. On top of that, IBRX trades at a lofty price‑to‑sales ratio above 70. For active traders, that combination—weak profitability, heavy dilution history, and rich valuation—means every regulatory headline can slam the stock hard.

Why Traders Are Watching IBRX Now

IBRX is back on every momentum trader’s screen because the narrative shifted fast. The catalyst was a harsh FDA Warning Letter on 2026/03/24, calling Anktiva promotions in a TV ad and podcast “false or misleading.” The agency flagged claims that implied Anktiva might cure or prevent all cancers and suggested broader indications and an unapproved subcutaneous route. When that letter hit daylight, IBRX shed about 21% in a single session and roughly $2B in market value evaporated.

That kind of one‑day flush tells you a lot. It says a big chunk of the ImmunityBio bull case was confidence in management’s story around Anktiva. Once the FDA questioned the messaging, traders started questioning everything: the commercial runway, the regulatory relationship, and even how to trust future updates.

The pain did not stop there. Separate updated Phase 2 data from the QUILT 3.078 glioblastoma study—showing median overall survival not yet reached—sparked another hit of around 12% in IBRX. On paper, that data point is nuanced. In the market, nuance lost. Traders saw uncertainty and sold first.

Now, multiple securities‑fraud class actions allege that ImmunityBio and Patrick Soon‑Shiong overstated Anktiva’s capabilities and business prospects during a class period from 2026/01/19 to 2026/03/24. Suits point straight at those same TV and podcast promotions. For short‑term trading, this is all about headline risk: every new filing, every legal advertisement, every FDA follow‑up can knock IBRX around. That makes ImmunityBio a textbook volatility play, but only for traders who respect risk and manage size.

More Breaking News

Conclusion

For active traders, ImmunityBio is a live case study in how fast sentiment can flip when the regulator steps in. IBRX went from a high‑beta cancer‑immunotherapy story to a stock dominated by questions over credibility, compliance, and communications. The FDA Warning Letter on Anktiva, the 21% single‑day dump, the additional 12% slide on glioblastoma data, and the wave of class actions together form a heavy overhang.

At the same time, the chart shows IBRX trying to stabilize in the mid‑$7s after the initial shock. Liquidity remains strong, and tight intraday ranges suggest short‑term equilibrium as traders digest the news. For those who trade headlines, ImmunityBio now trades more on press releases and court updates than on standard valuation metrics. The negative margins, cash burn, and rich price‑to‑sales multiple only amplify that sensitivity.

This is where discipline matters. Many in the Tim Sykes community focus on exactly these broken‑story setups—big gaps, emotional selling, and sharp bounces—but they do it with strict rules. As millionaire penny stock trader and teacher Tim Sykes, says, “There is always another play around the corner; don’t chase just because you feel FOMO.”. As Tim Sykes likes to remind traders, “Volatility is opportunity, but only if you cut losses quickly; otherwise it’s just another expensive lesson.” With IBRX, the opportunity is real, and so is the risk. Traders who step in need a plan, hard stops, and zero hesitation to hit the sell button if the next headline goes the wrong way.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Click Here for a Millionaire's POV on Trading IBRX

Millionaire's
POV on IBRX

Don't miss the next
big breakout.

GET POV
Tim Sykes

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”